Kelley A. Saia, MD

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Expertise includes: Treatment of substance use disorders in pregnancy and post-pregnancy, including opioid, alcohol, stimulant and marijuana use disorders; Trauma-informed care for pregnant persons with substance use disorder

Publications

  • Published 5/19/2025

    Iannella N, Momper J, Mirochnick M, Suhandynata RT, Saia K, Werler M, Jones HE, Wachman EM. Pharmacokinetics of Oral and Extended-release Naltrexone in Pregnant and Lactating Individuals and their Infants. J Addict Med. 2025 May 19. PMID: 40388713.

    Read at: PubMed

  • Published 5/13/2025

    Nelson-Rodriguez A, Saia K, Xie X, Momper J, Schiff DM, Wachman EM. Pharmacokinetics and Breast Milk Transfer to Infants of Subcutaneous Extended-Release Buprenorphine for the Treatment of Individuals with Opioid Use Disorder. Breastfeed Med. 2025 May 13. PMID: 40358655.

    Read at: PubMed

  • Published 2/17/2025

    Sousa A, Besong OTO, Wachman EM, Taglauer ES, Beane JE, Kefella Y, Koo JS, Saia K, Jones HE, Zhang H. Placental transcriptome analysis in opioid-exposed versus non-opioid exposed pregnancies. Placenta. 2025 Mar 25; 162:27-34. PMID: 39983471.

    Read at: PubMed

  • Published 7/1/2024

    Khazanchi R, Wachman EM, Schiff DM, Modest A, Saia KA, Hsu HE. Mandatory Child Protective Services Reporting for Substance-Exposed Newborns and Peripartum Outcomes: A Difference-in-Differences Analysis. JAMA Pediatr. 2024 Jul 01; 178(7):719-722. PMID: 38709513.

    Read at: PubMed

  • Published 5/21/2024

    Mantri S, Cheng AC, Saia K, Shrestha H, Amgott R, Bressler J, Werler MM, Carter G, Jones HE, Wachman EM. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy. Early Hum Dev. 2024 Jul; 194:106051. PMID: 38815498.

    Read at: PubMed

Education

  • University of Vermont, MD
  • Georgetown University, BSN
  • Hobart and William Smith Colleges, BA